NCT05635045View on ClinicalTrials.gov

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

May 7, 2024

Study Completion Date

June 12, 2024

Conditions
Transthyretin Amyloidosis
Interventions
DRUG

I 124-Evuzamitide

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Attralus, Inc.
All Listed Sponsors
collaborator

Attralus, Inc.

INDUSTRY

lead

Columbia University

OTHER

NCT05635045 - Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR | Biotech Hunter | Biotech Hunter